story of the week
Lenvatinib vs Sorafenib in First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lenvatinib Versus Sorafenib in First-Line Treatment of Patients With Unresectable Hepatocellular Carcinoma: A Randomised Phase 3 Non-Inferiority Trial
Lancet 2018 Feb 09;[EPub Ahead of Print], M Kudo, RS Finn, S Qin, KH Han, K Ikeda, F Piscaglia, A Baron, JW Park, G Han, J Jassem, JF Blanc, A Vogel, D Komov, TRJ Evans, C Lopez, C Dutcus, M Guo, K Saito, S Kraljevic, T Tamai, M Ren, AL ChengFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.